Screener
Xilio Therapeutics, Inc. XLO Q2 2026 earnings
Reported August 13, 2026 · Before market open
Revenue$18.7MBeat by $6.0M
EPS-$0.33Beat by $0.26
Revenue estimate$12.7M
EPS estimate-$0.59
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$4.8M
EPS estimate-$0.82
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Xilio Therapeutics, Inc. report Q2 2026 earnings?
- Xilio Therapeutics, Inc. (XLO) reported Q2 2026 earnings on August 13, 2026 before market open.
- What were Xilio Therapeutics, Inc.'s Q2 2026 revenue and EPS?
- Xilio Therapeutics, Inc. reported revenue of $18.7M and eps of $-0.33 for Q2 2026.
- Did Xilio Therapeutics, Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $12.7M by $6.0M. EPS beat the consensus estimate of $-0.59 by $0.26.
- How did Xilio Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 131.2% from $8.1M a year earlier and eps declined 106.3% from $-0.16.
- Where can I find Xilio Therapeutics, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-345753) and the 10-Q periodic report (0001193125-26-345759) directly on SEC EDGAR. The filing index links above go to sec.gov.
